Voyager Therapeutics (VYGR) Cash from Investing Activities (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Cash from Investing Activities data on file, last reported at $8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 80.34% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $92.3 million (up 117.76% YoY), and the FY2025 full-year result was $125.4 million, up 232.24% from the prior year.
• Cash from Investing Activities eased to $8.1 million in Q1 2026, from $47.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $64.4 million in Q3 2024 to a low of -$158.3 million in Q3 2023.
• A 5-year average of -$6.5 million and a median of $8.1 million in 2026 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 357.45% in 2022 and sank 762.93% in 2024, its largest moves.
• Tracing VYGR's Cash from Investing Activities over 5 years: stood at $14.1 million in 2022, then jumped by 90.75% to $26.8 million in 2023, then tumbled by 201.38% to -$27.2 million in 2024, then soared by 274.33% to $47.4 million in 2025, then tumbled by 82.92% to $8.1 million in 2026.
• Business Quant data shows VYGR's Cash from Investing Activities at $8.1 million in Q1 2026, $47.4 million in Q4 2025, and $34.9 million in Q3 2025.